ER/LA Opioid REMS

Registration


There is no cost for this educational activity. This course is available through the American Society of Addiction Medicine (ASAM) website. Click here to register and enroll. The course will open in a new window. 

NOTE: This course is no longer available through the ASAM website and the hyperlinks above have been removed.
 

The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

  • In 2011, almost 17,000 Americans died of drug overdose involving opioid analgesics.
  • 1 in 20 high school seniors reports abusing OxyContin.

The FDA approved a risk evaluation and mitigation strategy (REMS) for ER/LA opioid medications on July 9, 2012. The CO*RE/ASAM ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care course was developed by nationally renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units defined by the FDA blueprint for REMS education. ASAM also provides a unit addressing ER/LA opioids and addiction.In response to the growing problem of the abuse, misuse and diversion of (ER/LA) Opioid drugs, the FDA approved a REMS for ER/LA opioid medications on July 9, 2012. The ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care course was developed by nationally renowned experts from CO*RE (Collaborative for REMS Education) and incorporates all six units defined by the FDA blueprint for REMS education. 

The ER/LA Opioid REMS Course online has been approved for 3.0 AMA PRA Category 1 Credits™. Presented September 2014 by two distinguished faculty members, the course features all the FDA blueprint approved content developed by CO*RE, and an additional 30-minute session developed by ASAM entitled, "Is My Patient Opioid Addicted?" This online offering is available free of charge.

Who Should Attend

The intended audience is all prescribers of ER/LA Opioids which includes: pain specialists, primary care physicians, physician assistants, nurse practitioners, advanced practice nurses, dentists, addiction medicine physicians, psychiatrists and other physicians and clinicians. 

RPC Commercial Support Disclosure Statement

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

Course Outline

  • Assessing Patients for Treatment with ER/LA Opioid Analgesic Therapy
  • Initiating Therapy, Modifying Dosing, and Discontinuing Use of ER/LA Opioid Analgesics
  • Managing Therapy with ER/LA Opioid Analgesics
  • Counseling Patients & Caregivers about Safe Use of ER/LA Opioid Analgesics
  • General Drug Information for ER/LA Opioid Analgesics
  • Specific Drug Information for ER/LA Opioid Analgesic Products
  • Is My Patient Opioid Addicted? – Diagnosis and Management
  • Opioid Jeopardy – an Audience Interactive Learning Session

*This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment. 

Goals and Objectives

  1. Describe appropriate patient assessment for treatment with ER/LA opioid analgesics, evaluating risks and potential benefits of ER/LA therapy, as well as possible misuse.
  2. Apply proper methods to initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics, applying best practices including accurate dosing and conversion techniques, as well as appropriate discontinuation strategies.
  3. Demonstrate accurate knowledge about how to manage ongoing therapy with ER/LA opioid analgesics and properly use evidence-based tools while assessing for adverse effects.
  4. Employ methods to counsel patients and caregivers about the safe use of ER/LA opioid analgesics, including proper storage and disposal.
  5. Review/assess general and product-specific drug information concerning ER/LA opioid analgesics and identifying potential adverse effects of ER/LA opioids.

Acknowledgement

Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.

RPC Commercial Support Disclosure Statement

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

Course summary
Available credit: 
  • 3.00 AMA PRA Category 1 Credits
Course opens: 
12/31/2016
Course expires: 
10/01/2017
Cost:
$0.00
Rating: 
0

CME Information

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The ASAM designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.

This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 3.0 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. Click here for a full list of disclosures. 

Available Credit

  • 3.00 AMA PRA Category 1 Credits

Accreditation Period

Course opens: 
12/31/2016
Course expires: 
10/01/2017

Price

Cost:
$0.00
Please login or Create an Account to take this course.